Flora Peyvandi Introduces Breakthrough Protease-Resistant ADAMTS13 Enhancing VWF Regulation in Thrombotic Disorders
A new study published in Blood Advances by Prof. Flora Peyvandi and colleagues presents a study about a bioengineered, protease-resistant form of ADAMTS13, designed to enhance resistance to proteolytic degradation without compromising its functional regulation of von Willebrand factor (VWF)-posted on X:
“Mortality, diagnosis, and etiology of disseminated intravascular coagulation – A systematic review and meta-analysis: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.”
Recombinant ADAMTS13 has shown therapeutic potential in thrombotic disorders such as heritable TTP and is under investigation for use in acquired TTP and sickle cell disease. However, its susceptibility to degradation by proteases like plasmin limits its efficacy, especially under thrombo-inflammatory conditions. This study introduces protease-resistant ADAMTS13 variants—specifically modified in linker regions—that retain full VWF-cleaving function under flow. These stabilized forms resist cleavage by thrombin, FXIa, kallikrein, and neutrophil-derived enzymes, without compromising antithrombotic activity. The findings suggest that protease-resistant ADAMTS13 may enhance therapeutic durability in TTP and broaden its use in thrombosis-related diseases such as ischemic stroke and myocardial infarction.
Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation
Autors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Similar exciting news can be found in Hemostasis Today.
-
Apr 24, 2026, 09:38Luis Ferreira Moita: Rethinking Sepsis Care Through the Lancet Commission Initiative
-
Apr 24, 2026, 09:33Emmanuele Kouvousis: Do Calcium Supplements Increase the Risk of CVD Recurrence?
-
Apr 24, 2026, 09:19Stephen Bailey: Saving Lives Before Birth with Intrauterine Transfusions
-
Apr 24, 2026, 09:13Fatima Eltyeb Hago: Are We Doing More Harm Than Good with Combination Antithrombotic Therapy in AF?
-
Apr 24, 2026, 09:08Erica Sparkenbaugh: The Women Behind the UNC’s 12th Hemostasis Symposium
-
Apr 24, 2026, 09:07Michael Makris: When a Researcher Is Listed as First Author Without Knowing
-
Apr 24, 2026, 08:34Akmez Latona: Clauss vs PT-Derived Fibrinogen in Relation to Viscoelastic Clot Strength
-
Apr 24, 2026, 08:20Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange
-
Apr 24, 2026, 08:13Prasen Marella Highlights Recruitment Challenges in Stroke-Alzheimer’s Research at TS26 – UTHealth Houston Stroke